Shionogi-ViiV integrase inhibitor combination enters Phase III trials
This article was originally published in Scrip
Executive Summary
The Shionogi-ViiV Healthcare joint venture has begun the Phase III clinical development of a fixed-dose combination of its lead experimental oral integrase inhibitor with GlaxoSmithKline's marketed product, Kivexa/Epzicom (abacavir plus lamivudine).